| Literature DB >> 33369424 |
Cheng-Peng Sun1, Xin-Yue Zhang1, Christophe Morisseau2, Sung Hee Hwang2, Zhan-Jun Zhang3, Bruce D Hammock2, Xiao-Chi Ma1,4.
Abstract
Soluble epoxide hydrolase (sEH) is an α/β hydrolase fold protein and widely distributed in numerous organs including the liver, kidney, and brain. The inhibition of sEH can effectively maintain endogenous epoxyeicosatrienoic acids (EETs) levels and reduce dihydroxyeicosatrienoic acids (DHETs) levels, resulting in therapeutic potentials for cardiovascular, central nervous system, and metabolic diseases. Therefore, since the beginning of this century, the development of sEH inhibitors is a hot research topic. A variety of potent sEH inhibitors have been developed by chemical synthesis or isolated from natural sources. In this review, we mainly summarized the interconnected aspects of sEH with cardiovascular, central nervous system, and metabolic diseases and then focus on representative inhibitors, which would provide some useful guidance for the future development of potential sEH inhibitors.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33369424 PMCID: PMC7942193 DOI: 10.1021/acs.jmedchem.0c01507
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446